What Alcon PanOptix is
PanOptix is a diffractive trifocal IOL from Alcon. It distributes light to distance, intermediate and near focal ranges. In daily terms, the trial tested the road at 4 m, arm's-length work at 66 cm and reading at 40 cm.
The FDA approved it on August 26, 2019 under PMA P040020/S087. The main clinical model was the non-toric TFNT00. Toric versions correct corneal astigmatism on the same optical platform, but the pivotal acuity arm reported here did not separately test every toric model.
What it looks like
The image below is reproduced from the lens's own FDA regulatory filing, not manufacturer marketing artwork, so what is shown is exactly what the FDA reviewed and approved.
Source: FDA SSED, PMA P040020/S087, Figure 1
Where the data on this page comes from
FDA Summary of Safety and Effectiveness Data (SSED) — PMA P040020/S087 (PDF)
Every figure below comes from PanOptix's FDA Summary of Safety and Effectiveness Data (SSED) — the public document FDA published alongside approval, based on the pivotal trial Alcon submitted (PMA P040020/S087: 250 enrolled, 243 implanted, 12 U.S. sites, non-randomized, vision-assessor-masked, 6-month follow-up; 127 PanOptix and 113 monofocal-control first eyes analyzed for the acuity results below). Every number is cited to its table so you can check it directly.
One structural note: the SSED's numeric acuity, satisfaction, and disturbance tables are used below because they're published as text. Contrast sensitivity, by contrast, is presented only as graphs in this document (Figures 5–8) — where that's the case, we summarize the SSED's own stated conclusion rather than estimating exact numbers we can't verify from a chart image.
Visual acuity by distance
Bars show relative acuity — longer bar = sharper vision. Exact logMAR value (lower is better) and Snellen equivalent shown at right.
Source: FDA SSED, PMA P040020/S087, Table 23
This is the classic trifocal pattern: distance vision essentially matches the monofocal control, while both intermediate and near vision show a large, consistent advantage — reflecting the lens's three dedicated focal points. The trial met each statistical target it had set before the study began: distance vision was not worse than the control, while near and intermediate vision were better, according to the SSED's own conclusion (p.37–38).
Translated into tasks: average 66 cm vision was about 20/23 with PanOptix versus 20/43 with the control; at 40 cm it was about 20/25 versus 20/68. These are group averages under trial conditions, not a promise for one eye.
Contrast sensitivity — what the graphs show
The SSED's own stated conclusion, drawn from binocular contrast-sensitivity figures at both photopic (bright) and mesopic (low-light) conditions with and without glare (Figures 5–8, pp.30–33), is: "The binocular contrast sensitivity results were slightly reduced for the PanOptix IOL compared to the monofocal control IOL, however these differences were not clinically meaningful." No numeric per-spatial-frequency table accompanies this conclusion in the SSED, so we're reporting the document's own summary rather than reconstructing values from a chart image.
Patient satisfaction (IOLSAT questionnaire)
% of patients, IOL Satisfaction Questionnaire (IOLSAT).
Source: FDA SSED, PMA P040020/S087, Table 22
The full SSED gives the underlying numbers: 80.5% of PanOptix patients (99/123) answered “never” to needing glasses overall during the previous seven days, versus 8.2% of monofocal-control patients (9/110). For near tasks specifically, 83.6% versus 8.2% answered “never.” That is a strong patient-relevant benefit, and it met the study's planned target for superiority.
Visual disturbances (halos, glare, starbursts)
% of patients reporting at least "a little" bother (i.e., not "not bothered at all").
Source: FDA SSED, PMA P040020/S087, Table 20
These figures represent any degree of bother, from a little bit to very much, which is why the percentages look higher than the "spontaneous report" style figures we cite for some other lenses — it's a directed question rather than an unprompted mention. On the higher end of that same scale ("quite a bit" or "very much" bothered), the gap narrows but doesn't close: 11.1% of PanOptix patients versus 1.8% of control patients for halos, and 12.0% versus 1.8% for starbursts, with glare closer between groups (8.7% vs. 7.2%).
Possible limitations, based on this data
- More PanOptix patients reported being quite a bit or very much bothered by halos (11.1% vs. 1.8%) and starbursts (12.0% vs. 1.8%). Glare was closer between groups (8.7% vs. 7.2%). These are separate measures of bother at 6 months, not a single rate for all visual symptoms.
- Contrast sensitivity was slightly reduced versus the monofocal control; the SSED describes this as not clinically meaningful, but the underlying figures exist only as graphs, not a published numeric table.
- The clinical trial evaluated only the non-toric TFNT00 model — the toric versions (TFNT30/40/50/60) share the optical platform but were not separately tested in this pivotal study.
- This is one 6-month industry-sponsored registration trial (127 PanOptix eyes vs. 113 control) — a valid basis for FDA approval, but shorter and smaller than the accumulated real-world literature on this widely used lens.
- The trial average cannot predict one eye. Residual prescription, astigmatism, ocular surface, cornea, retina, optic nerve and IOL position can all change the result and should be checked if vision or symptoms are disappointing.
Who should discuss this lens
PanOptix gives a clear reason to consider it: the pivotal study showed large gains in unaided intermediate and near vision and in reported freedom from glasses. It also gives a clear reason for caution when night driving is non-negotiable: directed questioning found more halos, glare and starbursts than with the monofocal control. A preoperative personality label cannot predict who will be bothered. Ask whether your eye is medically suitable, then decide how you value the measured near benefit against the measured symptom risk.
How it compares
PanOptix is a trifocal lens within the broader full-range category — using three discrete diffractive focal points rather than a continuous extended range. For the category-level trade-offs against non-diffractive EDOF and enhanced monofocal designs, see Full Range / Trifocal / Multifocal. For a broader look at why some patients in this general lens category report dissatisfaction, see Why Do Some Presbyopia-Correcting IOL Patients Report Dissatisfaction?
Questions for your surgeon
- Does my retina, optic nerve, cornea or ocular surface make the trial results less applicable?
- How do you measure and discuss “any halo” versus severe bother in your own patients?
- What residual astigmatism would materially reduce my near or intermediate result?
- If night driving is central to my work, which exact alternative would you compare and which result would you use?
A note on how manufacturers present this same data
Materials built from this same trial for sales and marketing purposes commonly lead with the satisfaction and spectacle-independence figures shown above — which are genuine and strong — while presenting visual-disturbance data, if shown at all, less prominently, comparing against different lenses, or using bench-optics metrics instead of the patient-reported outcomes shown side-by-side here. Much of this material draws on internal "Data on File" studies that aren't independently published, and is frequently restricted to healthcare-professional distribution rather than intended for patients to read directly. We've used the public FDA record and shown the favorable and unfavorable results from the same trial together, because both halves matter to a patient weighing this decision.
If a sales slide uses MTF or a model-eye comparison, first read how IOLs are tested in the lab before treating that graph as a patient outcome.
A note on this review
This page is educational content, not a clinical trial result and not a personal recommendation. Every figure is sourced directly from the FDA's public SSED for PMA P040020/S087 and cited by table number so you can verify it yourself; where the source document presents a result only as a graph, we've said so rather than estimating numbers we can't confirm. Actual outcomes vary from patient to patient, and the right lens for you can only be determined by a qualified ophthalmic surgeon based on your individual eye measurements and health history.